These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10888628)

  • 1. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.
    Heile JM; Fong YL; Rosa D; Berger K; Saletti G; Campagnoli S; Bensi G; Capo S; Coates S; Crawford K; Dong C; Wininger M; Baker G; Cousens L; Chien D; Ng P; Archangel P; Grandi G; Houghton M; Abrignani S
    J Virol; 2000 Aug; 74(15):6885-92. PubMed ID: 10888628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.
    Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H
    Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
    Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Immunol; 2019; 10():1145. PubMed ID: 31178869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
    Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses.
    Seong YR; Choi S; Lim JS; Lee CH; Lee CK; Im DS
    Vaccine; 2001 Apr; 19(20-22):2955-64. PubMed ID: 11282207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.
    Guest JD; Wang R; Elkholy KH; Chagas A; Chao KL; Cleveland TE; Kim YC; Keck ZY; Marin A; Yunus AS; Mariuzza RA; Andrianov AK; Toth EA; Foung SKH; Pierce BG; Fuerst TR
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.
    Hadlock KG; Lanford RE; Perkins S; Rowe J; Yang Q; Levy S; Pileri P; Abrignani S; Foung SK
    J Virol; 2000 Nov; 74(22):10407-16. PubMed ID: 11044085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
    McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
    J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.
    Tarr AW; Backx M; Hamed MR; Urbanowicz RA; McClure CP; Brown RJP; Ball JK
    Antiviral Res; 2018 Dec; 160():25-37. PubMed ID: 30217650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.
    Li D; von Schaewen M; Wang X; Tao W; Zhang Y; Li L; Heller B; Hrebikova G; Deng Q; Ploss A; Zhong J; Huang Z
    J Virol; 2016 Dec; 90(23):10486-10498. PubMed ID: 27630242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
    Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
    Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response.
    Vijayamahantesh V; Patra T; Meyer K; Alameh MG; Reagan EK; Weissman D; Ray R
    J Virol; 2022 Jun; 96(12):e0052322. PubMed ID: 35612312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein.
    Flint M; Dubuisson J; Maidens C; Harrop R; Guile GR; Borrow P; McKeating JA
    J Virol; 2000 Jan; 74(2):702-9. PubMed ID: 10623732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
    Khera T; Behrendt P; Bankwitz D; Brown RJP; Todt D; Doepke M; Khan AG; Schulze K; Law J; Logan M; Hockman D; Wong JAJ; Dold L; Gonzalez-Motos V; Spengler U; Viejo-Borbolla A; Ströh LJ; Krey T; Tarr AW; Steinmann E; Manns MP; Klein F; Guzman CA; Marcotrigiano J; Houghton M; Pietschmann T
    J Hepatol; 2019 Apr; 70(4):593-602. PubMed ID: 30439392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
    Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
    Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
    Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
    mBio; 2017 May; 8(3):. PubMed ID: 28512091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.
    Fenouillet E; Lavillette D; Loureiro S; Krashias G; Maurin G; Cosset FL; Jones IM; Barbouche R
    J Biol Chem; 2008 Sep; 283(39):26340-8. PubMed ID: 18667425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteins.
    Liu J; Zhu L; Zhang X; Lu M; Kong Y; Wang Y; Li G
    Biotechnol Appl Biochem; 2001 Oct; 34(2):109-19. PubMed ID: 11592917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.
    Flyak AI; Ruiz S; Colbert MD; Luong T; Crowe JE; Bailey JR; Bjorkman PJ
    Cell Host Microbe; 2018 Nov; 24(5):703-716.e3. PubMed ID: 30439340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.